Boston, MA 05\/21\/2014 (wallstreetpr) \u2013 The cancer treatment focused Provectus Pharmaceuticals Inc (NYSEMKT:PVCT)<\/b> has announced a new addition to its strategic advisory board. The announcement comes on the wake of the elevation of the stock to a senior capital market \u2013 NYSEMKT.<\/p>\n
The company announced that Jacob M. Plotsker will join its strategic board to help guide the company through growth and maximization of shareholder value.<\/p>\n
As Provectus seeks to grow, the company needs the best of industry talents. Therefore, it continues to tap talents to its management team to support its growth agenda especially now that it is at the full glare of many investors by virtue of its presence on NYSEMKT platform. The company\u2019s moves are now tracked closely as investors seek to understand its business thesis before they can make big bets on its future.<\/p>\n
Highly experienced adviser<\/b><\/p>\n
Provectus Pharmaceuticals Inc (NYSEMKT:PVCT)\u2019s latest addition to the strategic advisory board comes with a wealth of experience in various aspects of pharmaceutical industry. Mr. Plotsker, 46, is a director at Bayer Healthcare where he is in charge of IUS Strategy and Lifecycle Management. He started his career with Deloitte & Touche as a staff accountant. His career in the pharmaceutical space started at the U.S. drug giant Pfizer Inc (NYSE:PFE).<\/b> At Pfizer Mr. Plotsker served for 16 years and rose through the ranks to handle increasing responsibilities in the Finance and marketing department.<\/p>\n
Mr. Plotsker also had stints at Organon Biosceinces\/Schering Plough and Teva Pharmaceuticals as the head of marketing and senior director of operations.<\/p>\n
A member most welcomed<\/b><\/p>\n
According to Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) CEO Craig Dees, Mr. Plotsker is most welcomed to the strategic advisory board of the company. As a seasoned executive with widespread experienced in matter issues, in the U.S. and globally, Mr. Dees expects many things from the new Strategic Advisory board member.<\/p>\n
The company seeks to win the confidence of as many investors as possible so that it can raise funds for its various growth projects. Winning the confidence of the investor community starts by having a dependable management team in place. Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) believes that its ongoing talents acquisition will boost its image among investors and support its goals.<\/p>\n
The listing of the stock on NYSEMKT marked a milestone for the company has it is now right in front of a broad base of shareholders.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 05\/21\/2014 (wallstreetpr) \u2013 The cancer treatment focused Provectus Pharmaceuticals Inc (NYSEMKT:PVCT) has announced a new addition to its strategic advisory board. The announcement […]<\/p>\n","protected":false},"author":12,"featured_media":23125,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[993,6826,2745,6825],"stock_ticker":[],"class_list":["post-23124","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysepfe","tag-nysemktpvct","tag-pfizer-inc-nysepfe","tag-provectus-pharmaceuticals-inc-nysemktpvct","entry"],"acf":[],"yoast_head":"\n